| Hazard Information | Back Directory | [Uses]
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential[1]. | [in vivo]
Adintrevimab (9.25, 55, 333, or 2,000?μg; i.p.; once) provids protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner[1].
Adintrevimab (5-25?mg/kg; i.v.; once) provids protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner[1].
| Animal Model: | Syrian golden hamsters (5-6-week-old females; 75-125 g) infected with SARS-CoV-2/WA1/2020[1].
| | Dosage: | 9.25, 55, 333, or 2,000?μg (average range: 0.1 to 20?mg/kg) | | Administration: | Intraperitoneal injection; single dose | | Result: | Showed significant reduction in lung viral load and virus-induced lung pathology. |
| Animal Model: | Rhesus macaques (5.6-8.8?years old; 6 females [4.4-6.3?kg] and 6 males [6.1-8.5?kg]) infected with SARS-CoV-2/WA1/2020[1]. | | Dosage: | 5?mg/kg, 25?mg/kg | | Administration: | Intravenous injection; single dose | | Result: | Reduced pulmonary inflammation. |
| [References]
[1] Elizabeth E Zumbrun, et al. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. Antimicrob Agents Chemother. 2022 Dec 15;e0135322. DOI:10.1128/aac.01353-22 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|